SELLAS Life Sciences (SLS) Other Operating Expenses (2011 - 2023)
SELLAS Life Sciences (SLS) posted quarterly Other Operating Expenses of $184000.0 for Q1 2023, up 2144.44% year-over-year from $8198.0 in Q1 2022, and up 48.39% quarter-over-quarter from $124000.0 in Q3 2022.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Other Operating Expenses (2011 - 2023) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Other Operating Expenses for 14 consecutive years, with $184000.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Other Operating Expenses rose 2144.44% year-over-year to $184000.0; the TTM figure through Dec 2023 stood at $184000.0 (down 43.21% YoY), while the FY2022 annual figure was $10.1 million, up 71.19% from the prior year.
- Other Operating Expenses advanced to $184000.0 in Q1 2023 per SLS's latest filing, from $124000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $5.7 million in Q4 2021 and bottomed at -$178000.0 in Q1 2019.
- Historically, Other Operating Expenses has averaged $415466.7 across 5 years, with a median of -$18000.0 in 2019.
- Annual changes were most pronounced in 2021 — Other Operating Expenses plunged 668.42% — and 2023, when it jumped 2144.44%.
- SELLAS Life Sciences' Other Operating Expenses stood at -$21000.0 in 2019, then surged by 190.48% to $19000.0 in 2020, then soared by 29900.0% to $5.7 million in 2021, then slumped by 97.82% to $124000.0 in 2022, then jumped by 48.39% to $184000.0 in 2023.
- Business Quant data shows SLS's Other Operating Expenses at $184000.0 in Q1 2023, $124000.0 in Q3 2022, and $209000.0 in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 184,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Mar 31, 2022 | -9,000.00 |
| Dec 31, 2021 | 5.70 Mn |
| Sep 30, 2021 | -108,000.00 |
| Jun 30, 2021 | -160,000.00 |
| Mar 31, 2021 | -158,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | -158,000.00 |
| Mar 31, 2020 | -79,000.00 |
| Dec 31, 2019 | -21,000.00 |
| Sep 30, 2019 | -18,000.00 |
| Jun 30, 2019 | 885,000.00 |
| Mar 31, 2019 | -178,000.00 |
| Dec 31, 2018 | 979,000.00 |
| Sep 30, 2018 | 2.77 Mn |
| Jun 30, 2018 | 602,000.00 |
| Mar 31, 2018 | -2.31 Mn |
| Dec 31, 2017 | -102,000.00 |